Fortress Biotech, Inc. Quarterly report [Sections 13 or 15(d)]

Asset Purchase and Merger Agreements - Checkpoint CVR Agreement (Details)

Asset Purchase and Merger Agreements - Checkpoint CVR Agreement (Details) - Checkpoint Common Stock Warrants $ / shares in Units, $ in Thousands	Mar. 09, 2025 USD ($) $ / shares shares
Number of warrants to purchase shares \| shares	5,853,659
Exercise price of warrants \| $ / shares	$ 3.62
Sun Pharmaceutical Industries, Inc.
Termination fee payable	$ 12,500
Checkpoint Common Stock Warrants \| Sun Pharmaceutical Industries, Inc.
Cash consideration per each share outstanding \| $ / shares	$ 4.1
Maximum contingent consideration per each outstanding share \| $ / shares	$ 0.7
Termination period	1 year
Milestone deadline date determination term	36 months
Checkpoint Common Stock Warrants \| Sun Pharmaceutical Industries, Inc. \| If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of once every three weeks
Contingent cash consideration upon achievement of milestone	$ 700
Checkpoint Common Stock Warrants \| Sun Pharmaceutical Industries, Inc. \| If Milestone is first achieved on or prior to date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule of more frequent than once every three weeks
Contingent cash consideration upon achievement of milestone	450
Checkpoint Common Stock Warrants \| Sun Pharmaceutical Industries, Inc. \| If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule once every three weeks
Contingent cash consideration upon achievement of milestone	450
Checkpoint Common Stock Warrants \| Sun Pharmaceutical Industries, Inc. \| If Milestone is first achieved on or after the date that is 12 months prior to Milestone Deadline Date and approval for a dosing schedule more frequent than once every three weeks
Contingent cash consideration upon achievement of milestone	$ 200